Cargando…
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
Topoisomerase I inhibitors constitute a new class of anti-cancer agents. Recently, topotecan and irinotecan were registered for clinical use in ovarian cancer and colorectal cancer respectively. Cytotoxicity of topoisomerase I inhibitors is S-phase specific, and in vitro and in vivo studies have sug...
Autores principales: | Gerrits, C. J., de Jonge, M. J., Schellens, J. H., Stoter, G., Verweij, J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228255/ https://www.ncbi.nlm.nih.gov/pubmed/9328159 |
Ejemplares similares
-
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.
por: Gerrits, C. J., et al.
Publicado: (1997) -
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
por: Gerrits, C. J., et al.
Publicado: (1996) -
Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
por: Schellens, J. H., et al.
Publicado: (1996) -
Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38
por: Mathijssen, R H J, et al.
Publicado: (2002) -
Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion.
por: Ma, J., et al.
Publicado: (1994)